IFPA Forum Americas 2025: “Towards More Equitable, Person-Centered Care for All People Living with Psoriatic Disease in the Americas”
On April 4, 2025, IFPA will host the IFPA Forum 2025 for…
Data of InnoCare’s ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a…
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15%…
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…